Abstract
In this study, 1-(3-(4-chlorophenyl)-5-methylthio-1H-1, 2, 4-triazol-1-y1)-butan-1-one discovered previously in our lab was selected as a inhibitor of human dihydroorotate dehydrogenase (HsDHODH) for structural optimization. The co-crystal of HsDHODH with the hit was obtained and analyzed for guiding the subsequent structural optimization. As a result, a series of novel triazole derivatives were designed and synthesized as potent HsDHODH inhibitors. Among them, compound (3-(4-chlorophenyl)-5-ethylthio-1H-1, 2, 4-triazol-1-y1)-furan-2-y1-methanone displayed high potency in the inhibition of HsDHODH with an IC50 value of 1.50 μmol·L-1. Meanwhile, the structure-activity relationships were analyzed based on the biological data and the co-crystal structure. These results provide a valuable reference for optimization of 1H-1, 2, 4-triazole derivatives as HsDHODH inhibitors in the future.
| Original language | English |
|---|---|
| Pages (from-to) | 264-270 |
| Number of pages | 7 |
| Journal | Yaoxue Xuebao |
| Volume | 52 |
| Issue number | 2 |
| DOIs | |
| State | Published - 12 Feb 2017 |
| Externally published | Yes |
Keywords
- Autoimmune disease
- Complex co-crystal structure
- Human dihydroorotate dehydrogenase inhibitor
- Structure-activity relationship
- Triazole derivative